The European Commission has approved SKYRIZI® for the treatment of active psoriatic arthritis in adults.

The European Medicines Agency (EMA) has accepted to review Boehringer Ingelheim’s marketing authorization application (MAA) for spesolimab to treat flares in generalised pustular psoriasis (GPP).

The AbbVie program features IPC Board Member Bruce Strober’s Grand Rounds, a tutorial explaining the current method of measuring the severity of psoriasis, why this limits proper care and treatment for psoriasis patients, how IPC’s Disease Severity Reclassification Project solves these problems, and how clinicians can implement this new classification method.

Amgen and Otezla® (apremilast) have partnered with Allan Avendaño, makeup artist to Hollywood A-listers, for the INSIDE LOOK campaign to share his journey living with plaque psoriasis and the difficulties of being in his demanding role and dealing with a chronic skin condition.

Dermavant Sciences announced on June 3, 2021 that it has submitted a New Drug Application to the U.S. Food and Drug Administration for tapinarof for the treatment of mild, moderate and severe plaque psoriasis in adult patients.

Conozca cómo se mide actualmente la gravedad de la psoriasis y por qué es necesario un cambio, cómo el IPC organizó el proceso Delphi que se utilizó para redefinir la clasificación de la gravedad, las implicaciones y los efectos que tiene el resultado en los proveedores de tratamiento de la psoriasis y los pacientes con psoriasis y, en última instancia, cómo los pacientes se beneficiarán de esto. esfuerzo.

Learn how psoriasis severity is currently measured and why a change is necessary, how IPC organized the Delphi process that was used to redefine severity classification, implications and effects the output has on psoriasis treatment providers and psoriasis patients, and ultimately how patients will benefit from this endeavor.

Janssen Pharmaceutical Companies of Johnson & Johnson published the long-term data of the third phase of the DISCOVER-2a study.

Sun Pharmaceutical Industries Inc. announces results from their five-year Phase-3 efficacy and safety clinical trial for ILUMYA®(tildrakizumab-asmn) based on a pooled analysis of the ReSURFACE 1 and ReSURFACE 2 extension.

IPC welcomes Dermavant as a new 2021 corporate member.